TEMPERATURE-DEPENDENT IMMUNOREACTIVE ASSAY TO SCREEN FOR DIGOXIN-LIKE IMMUNOREACTIVE FACTOR(S)

被引:0
|
作者
GUEDENEY, X [1 ]
CHANEZ, C [1 ]
GRENIER, A [1 ]
SCHERRMANN, JM [1 ]
机构
[1] HOP FERNAND WIDAL,INSERM,U26,200 RUE FAUBOURG ST DENIS,F-75475 PARIS 10,FRANCE
关键词
VARIATION; SOURCE OF; RADIOIMMUNOASSAY; NA+K+ATPASE;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Endogenous circulating digoxin-like immunoreactive factors (DLIF) are known to cross-react with antibodies to digoxin and to inhibit Na+/K+-transporting ATPase (Na+K+ATPase; EC 3.6.1.37). Moreover, increasing the immunoassay temperature from 4 to 37-degrees-C markedly decreases DLIF from human cord serum. We tested several compounds, including hormonal steroids, bile salts, lipids, and methionine-enkephalin, for their ability to cross-react with two commercially available I-125 digoxin RIAs, to inhibit porcine Na+K+ATPase, and to see whether they present the same incubation temperature dependence as human cord serum. Except for methionine-enkephalin, all compounds were inhibitors of Na+K+ATPase in the range of 1-10 mmol/L. Progesterone exhibited the highest cross-reactivity in the two RIAs. The apparent digoxin immunoreactivity for the majority of the cross-reacting steroids, bile salts, and linoleic acid was markedly decreased by increasing the incubation temperature from 4 to 37-degrees-C, whereas estriol, pregnanediol, and nonspecific compounds (e.g., ethanol, human serum albumin) did not appear to be temperature-sensitive. Both lysophosphatidyl lipids gave an increased apparent digoxin concentration with increasing incubation temperature. Our data suggest that numerous weakly cross-reactive compounds can parallel the response of human cord serum. However, the temperature-dependent effect could be an additional criterion for identifying DLIF.
引用
收藏
页码:1900 / 1904
页数:5
相关论文
共 50 条
  • [21] Digoxin-like immunoreactive substance in nonoliguric hyperkalemia
    Mildenberger, E
    Oels, K
    Bauer, K
    Paul, M
    Versmold, HT
    PEDIATRIC RESEARCH, 2002, 52 (05) : 787 - 787
  • [22] RELATION OF DIGOXIN-LIKE IMMUNOREACTIVE SUBSTANCE TO PREECLAMPSIA
    FRIEDMAN, HS
    XENAKIS, E
    VORPERIAN, V
    BABB, B
    FARRER, S
    TRICOMI, V
    CLINICAL RESEARCH, 1989, 37 (03): : A854 - A854
  • [23] DIGOXIN-LIKE IMMUNOREACTIVE SUBSTANCE AND PRETERM LABOR
    AYHAN, A
    YARALI, H
    DIKER, I
    URMAN, B
    DEVELIOGLU, O
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1990, 30 (02) : 75 - 77
  • [24] DOES AN ENDOGENOUS DIGOXIN-LIKE IMMUNOREACTIVE FACTOR PARTICIPATE IN THE DEVELOPMENT OF CARDIOMEGALY
    SCHREIBER, V
    KOLBEL, F
    COR ET VASA, 1982, 24 (04) : 228 - 232
  • [25] MARKED DIGOXIN-LIKE IMMUNOREACTIVE FACTOR INTERFERENCE WITH AN ENZYME-IMMUNOASSAY
    KARBOSKI, JA
    GODLEY, PJ
    FROHNA, PA
    HORTON, MW
    REITMEYER, WJ
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1988, 22 (09): : 703 - 705
  • [26] ISOLATION OF DIGOXIN-LIKE IMMUNOREACTIVE FACTOR FROM ADRENAL-CORTEX
    SHAIKH, IM
    VALDES, R
    CLINICAL CHEMISTRY, 1990, 36 (06) : 1156 - 1156
  • [27] Deglycosylated products of endogenous digoxin-like immunoreactive factor in mammalian tissue
    Qazzaz, HMAM
    Goudy, SL
    Valdes, R
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (15) : 8731 - 8737
  • [28] DIGOXIN-LIKE IMMUNOREACTIVE FACTOR(S) IN HUMAN GONADOTROPIN STIMULATED FOLLICULAR-FLUID
    JAKOBI, P
    KRIVOY, N
    EIBSCHITZ, I
    ZISKIND, G
    BARZILAI, D
    PALDI, E
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 69 (01): : 209 - 211
  • [29] INTERFERENCE OF DIGOXIN-LIKE IMMUNOREACTIVE SUBSTANCES WITH TDX DIGOXIN-II ASSAY IN DIFFERENT PATIENTS
    AVENDANO, C
    ALVAREZ, JS
    SACRISTAN, JA
    ADIN, J
    ALSAR, MJ
    THERAPEUTIC DRUG MONITORING, 1991, 13 (06) : 523 - 527
  • [30] DIGOXIN-LIKE IMMUNOREACTIVE SUBSTANCE IN RENAL PATIENTS AND IN INFANTS
    DARCY, PF
    PHARMACY INTERNATIONAL, 1984, 5 (07): : 163 - 164